RGEN · NASDAQ · STOCK
Repligen (RGEN) Stock Analysis
$174.03
52W $100.99 – $198.87
57/100
$9.81B
235.0
1.08
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is RGEN Bullish or Bearish?
Bullish.
Innellis AI committee rates Repligen (RGEN) Buy with a composite score of 57/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +17.69 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -2.31 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — 4 consecutive earnings beats -- consistent execution. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.26) -- balance sheet can absorb a shock — Risk
Bear Case
- P/E of 262.3 is expensive by classic value standards — Value
- Price-to-book of 4.4x prices in significant intangible value — Value
- ROE of only 2.0% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 20.6% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
57/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 49%
of 192 Healthcare peers
Value Analyst
bearish
38
/ 100 · High confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 262.3 is expensive by classic value standards
Growth Analyst
bullish
77
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 4 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.26) -- balance sheet can absorb a shock
− Bollinger bandwidth of 20.6% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
53
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 57.4 to 57.3.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
45.4
Neutral
MACD Histogram
-2.704
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$173.33
Resistance
$174.61
Bollinger %B
0.32
Inside Bands
Price vs Moving Averages
EMA 9
$176.51
Below
EMA 21
$177.93
Below
EMA 50
$170.93
Above
EMA 200
$150.03
Above
Fundamental Analysis
Valuation
51
Growth
94
Profitability
33
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
235.0×
P/B Ratio
4.64×
PEG Ratio
0.28
Dividend Yield
0.00%
52W High
$198.87
52W Low
$100.99
Quality & Growth
ROE
232.1%
ROA
165.8%
Gross Margin
5105.1%
Operating Margin
831.7%
Revenue Growth YoY
—
Debt / Equity
0.33
AI Fundamental Assessment
P/E ratio of 235.0 (rich relative to a 15-40x range); Price-to-book of 4.6x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 2.3%; Return on assets of 1.7%; Net margin of 5.3%; Gross margin of 51.1%; Current ratio of 9.05 (healthy short-term liquidity); Debt-to-equity of 0.33; Free cash flow per share is positive (1.96); Most recent quarter beat estimates by 18.0%; 4 consecutive earnings beats; EPS growth accelerating (-2.0% -> +12.5% QoQ); Average YoY EPS growth of 46.0%; Analyst estimates rising over recent quarters
Get the Full RGEN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →